{
    "nct_id": "NCT03401112",
    "official_title": "A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-Î²0 Thalassemia)",
    "inclusion_criteria": "* Male or female participants with confirmed SCA\n* Age 18 to 55 years, inclusive\n* For participants on HU, must have been on a stable dose for at least 60 days prior to screening\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* Total hemoglobin >12.5 or <6 grams/deciliter\n* Red blood cell transfusion within 60 days of baseline\n* >7 hospitalizations for vaso-occlusive crises (VOCs) within the last year\n* Estimated glomerular filtration rate <50 milliliter/minute\n* Aspartate aminotransferase/alanine aminotransferase >3x the upper limit of normal",
    "miscellaneous_criteria": "Key"
}